Cardiologic Abnormalities in Noonan Syndrome: Phenotypic Diagnosis and Echocardiographic Assessment of 118 Patients

MICHAEL BURCH, MB, MRCP,* MICHAEL SHARLAND, MB, MRCP,
Elliott SHINEBOURNE, MD, FRCP,* GILLIAN SMITH, BSc,
MICHAEL PATTON, MD, FRCP, WILLIAM McKENNA, MD, FACC

London, England, United Kingdom

Objectives. The purpose of this study was to determine the incidence of cardiologic abnormalities in Noonan syndrome.

Background. The incidence of cardiac abnormalities in Noonan syndrome remains unknown, largely because of such difficulties as assembling a substantial cohort, ensuring a correct phenotypic diagnosis and providing accurate definitions of the most frequent abnormalities—pulmonary stenosis and left ventricular hypertrophy.

Methods. A cohort of 145 patients was assembled, and before cardiologic assessment two independent geneticists scrutinized the phenotype. The diagnosis was confirmed in 118 patients, and they were studied by two-dimensional and Doppler echocardiography.

Results. A dysplastic pulmonary valve was present in eight patients (7%) and was associated with significant stenosis in six (75%) of the eight. Significant stenosis was present in 22 (20%) of 110 patients without dysplasia. Left ventricular hypertrophy was present in 29 patients (25%) without significant pulmonary stenosis. Localized anterior septal hypertrophy was the most common pattern in 12 (41%) of 29 patients. Diffuse hypertrophy involving the entire septum and the free wall was present in nine patients (31%) and was severe (>1.7 cm) in five. Other abnormalities included secundum atrial septal defects (10%).

Conclusions. The high incidence of cardiac abnormalities suggests that echocardiographic and Doppler evaluation of patients with the Noonan phenotype is important because it will aid in genetic counseling and in the assessment of the natural history of—and, ultimately, identification of the gene(s) responsible for—Noonan syndrome.

(J Am Coll Cardiol 1993;22:1189–92)
continuous wave Doppler ultrasound (16,17). Right ventricular outflow velocity was assessed by Doppler study before pulmonary artery flow velocity to determine any significant subvalvular obstruction (18). Pulmonary regurgitation was assessed according to previously published methodology (19).

The diagnosis of left ventricular hypertrophy was made when wall thickness exceeded 2 SD for an age-matched control group. The definition of hypertrophy in Noonan syndrome is complicated by the frequent association of pulmonary stenosis, which may result in septal hypertrophy and mimic hypertrophic cardiomyopathy (20). Therefore any patient with septal hypertrophy and pulmonary artery Doppler velocity >200 cm/s (arbitrarily taken as that velocity below which right ventricular hypertrophy would be unlikely) was excluded from calculations of the incidence of left ventricular hypertrophy. Right ventricular hypertrophy was defined as a two-dimensional echocardiographic end-diastolic wall thickness >2 SD from age-related normal mean values.

Significant pulmonary stenosis was defined as a pulmonary artery Doppler velocity >300 cm/s, previously taken to indicate significant stenosis (21), or previous intervention (surgical valvotomy or balloon valvuloplasty). Abnormal pulmonary artery Doppler velocity was defined as a velocity >2 SD from the mean value of the normal, control population.

The control group was determined specifically for this study. Analysis of echocardiograms was performed without knowledge of the phenotypic diagnosis. Statistical analysis was performed using a t test. Significance was assumed at the 5% level. Results are expressed as mean value ± SD.

Results

Patient selection. From the 145 patients evaluated by the clinical geneticists, 118 (65 male, 53 female patients aged 1 week to 41 years [mean 10 years]) fulfilled the criteria for the phenotypic diagnosis of Noonan syndrome.

Cardiac Abnormalities

Pulmonary stenosis. Dysplastic valves. The pulmonary valve was dysplastic in eight patients (7%) and was defined as significantly stenotic in six (75%) of the eight. Intervention had been undertaken in three patients (two had surgical valvotomy; one had balloon valvuloplasty). A systolic velocity <300 cm/s with moderate pulmonary regurgitation was revealed in both surgical cases. Conversely, a systolic velocity >300 cm/s without regurgitation was found in the child who had undergone balloon valvuloplasty. All Doppler velocities in the patients who did not undergo surgery were >2 SD from our normal mean value (180 cm/s).

Nondysplastic valves. Significant stenosis in nondysplastic pulmonary valves was present in 22 (20%) of 110 patients. Intervention was undertaken in 17 patients (15 had surgical treatment; two had balloon valvuloplasty). Of these the systolic gradient was >300 cm/s in 1 patient (after surgery), and pulmonary regurgitation was moderate in 10 and mild in 6. A pulmonary artery Doppler flow velocity >2 SD from our normal mean value was found in 48 other patients (44%); however, a murmur was audible in only 22 (46%).

Ventricular hypertrophy. Wall thicknesses in relation to that of age-matched control subjects are shown in Figure 1. Overall left ventricular hypertrophy was present in 29 (25%) of 118 patients, and in this group there was a positive correlation with right ventricular wall thickness (r = 0.7, p < 0.05). Right ventricular hypertrophy was present in 20 (17%) of 118 patients, and significant pulmonary stenosis was present in 7 (35%) of the 20 and left ventricular hypertrophy in 8 (40%). Isolated septal hypertrophy was present in two
additional patients who had pulmonary artery Doppler flow velocity >200 cm/s. However, they were not considered to have left ventricular hypertrophy for the reasons defined earlier (see Echocardiography).

Maximal left ventricular wall thickness, in the 29 patients with hypertrophy, was at the upper anterior septum in 26 patients, the free wall in 2 and the lower anterior septum in 1. Hypertrophy involved the anterior septum in all 29 patients. In 12 patients (41%) it was confined to the anterior septum, and in 5 of these 12 it was a localized upper septal bulge (Fig. 2). In eight patients (28%) the posterior septum was also involved. An additional nine patients (31%) had diffuse hypertrophy involving the anteroseptal and posteroseptal regions and the free wall. Severe hypertrophy was present in five of the latter nine patients, and maximal wall thickness ranged from 1.7 to 2.7 cm (mean 2.3 ± 0.4) (Fig. 3). Systolic anterior motion of the mitral valve was present in all five patients. It was complete, with septal and anterior leaflet contact (22), in one patient who had a gradient of 64 mm Hg, but the gradient was <36 mm Hg in the other four. None of the patients with ventricular hypertrophy had an affected first-degree relative on family screening, nor was there a family history of sudden death in early adult life. In addition, there was no history of syncope, and only one patient (an infant) had evidence of cardiac failure.

Other Cardiac Abnormalities

Other cardiac abnormalities were common (Table 1). All but three of the septal defects had been corrected.

None of the three patients with aortic valve anomalies had left ventricular hypertrophy. A supravalvular aortic ridge has not been previously described in Noonan syndrome.

Discussion

To overcome the inherent difficulties of assessing the incidence of cardiac problems in Noonan syndrome, this study required a high level of genetic input. Cardiologic bias was removed by not specifically drawing from cardiac clinics. Furthermore, the large cohort enabled an accurate assessment to be made. Cardiac abnormalities were common, particularly pulmonary stenosis and ventricular hypertrophy. Some of the diagnoses reported in Noonan syndrome, however, such as disorders of the aortic valve sinuses and root (23,24), were not seen, in contrast to the Marfan or Turner syndrome, where aortic valve and aortic root problems are more common (25,26).

Pulmonary stenosis. Only a minority of patients in our study had the dysplastic valves thought typical of Noonan syndrome. However, those with dysplastic valves were more likely to need intervention and were less likely to have a satisfactory result, which is consistent with previous reports highlighting the difficulties of dilating dysplastic valves (14,27,28). Thus, the outcome of intervention is more likely to reflect the presence or absence of dysplasia rather than Noonan syndrome as such.

Ventricular hypertrophy. It is uncertain whether the unexplained left ventricular hypertrophy seen in 25% of patients in this study represents hypertrophic cardiomyopathy. We recently reported histologic similarity between the hypertrophy of Noonan syndrome and hypertrophic cardiomy-
opathy (29). The latter is a genetically heterogeneous disease, approximately 50% of patients having a missense mutation in the gene encoding beta-cardiac heavy chain myosin (30). The echocardiographic morphology has been well described elsewhere (31) and, although similar, it appears subtly different to that in patients with Noonan syndrome. In this study hypertrophy was often confined to the upper anterior septum and was only rarely severe and diffuse, which is the converse of the appearance of hypertrophic cardiomyopathy. (The electrocardiogram was not used, and although it can be helpful in diagnosing hypertrophy [32], it is less specific than echocardiography.) The clinical course of the two diseases is also dissimilar. To our knowledge, sudden death has not been reported in Noonan syndrome, although it is common in hypertrophic cardiomyopathy (33,34). Given the recent mapping of a gene for familial hypertrophic cardiomyopathy to chromosome 14q13 (35), linkage studies in Noonan syndrome are feasible and would be the final arbiter of whether the two conditions share a common etiology and prognosis.

Conclusions. The high incidence of cardiac abnormalities, particularly left ventricular hypertrophy, pulmonary stenosis, and secundum atrial septal defects, in the present series of patients studied here confirms the importance of cardiological evaluation in the phenotypic assessment of patients with Noonan syndrome.

References